Developer docs
API playgroundTry for free, no card

Search company profiles

OtoNexus Medical Technologies Inc.

Full company profile

uuid0000m65

Namestring
OtoNexus Medical Technologies Inc.
Legal namestring
OtoNexus Medical Technologies Inc.
Websiteurl
otonexus.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

OtoNexus Medical Technologies Inc. is a pre-revenue, venture-backed medical device company developing the Novoscope, a handheld ultrasound otoscope that miniaturizes a through-air ultrasound sensor into the tip of a disposable ear speculum and applies a proprietary algorithm to detect middle ear effusion and differentiate bacterial from viral infections in approximately two seconds. The technology is housed in a point-of-care device intended to replace subjective conventional otoscopy for frontline pediatric and primary-care decision-making, with direct EMR integration to transfer exam results, images, and video into patient records. The company was founded by Dr. George Gates, a practicing ENT surgeon, and Dr. Mark Moehring, an ultrasound systems expert and inventor of 16 issued ultrasound patents, and is led by Chair and CEO Caitlin Cameron with a leadership team drawn from Philips Healthcare, Fujifilm SonoSite, GE Healthcare, and Verathon.

The company protects its platform with more than 110 granted patents covering the through-air ultrasound modality, transducer design, and proprietary classification algorithm, and was selected for the FDA Safer Technologies Program (STeP) in December 2023, providing structured FDA engagement and an expedited review pathway. The commercial model is razor/razorblade: the Novoscope is sold or placed as durable capital equipment in clinics, while each exam consumes a single-use disposable tip, creating recurring consumables revenue that scales with installed base utilization. Target customers are primary care physicians, pediatricians, nurse practitioners, and physician assistants, with secondary segments in children's hospitals, pediatric emergency departments, and payers seeking to reduce unnecessary antibiotic prescriptions and downstream costs from misdiagnosed otitis media.

OtoNexus is headquartered near Seattle, Washington, is classified as a Micro Company (11-50 employees), and has raised approximately $13 million in equity from Keiretsu Capital and Keiretsu Forum members since inception, supplemented by non-dilutive SBIR grants from NIH ($1.15 million Fast-Track in 2017) and NSF (Phase I, Phase II, and Phase IIB). The company has built clinical and development partnerships with Fraunhofer IPMS for transducer co-development, with Mayo Clinic and Mary Bridge Children's Hospital for clinical validation, and is a member of three pediatric device consortia (CTIP, Southwest Pediatric Device Consortium, Philadelphia Pediatric Medical Device Consortium). Products are not yet commercially available, and the company is positioning itself for market entry pending FDA clearance.

Short descriptiontext

OtoNexus Medical Technologies is a pre-revenue medical device company developing the Novoscope, an AI-driven ultrasound otoscope that detects bacterial middle ear infections in pediatric and primary care settings through a razor/razorblade model combining a capital device with single-use disposable tips.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBellevue, United States
HQ citystring
Bellevue
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device diagnostics, ultrasound otoscope technology, ear infection detection, pediatric medical devices, antibiotic stewardship solutions
Industry1 code
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Diagnostic Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Ultrasound Otoscope Device Sales
TypeHardware Sales
Description

The ultrasound otoscope is sold (or placed) as durable capital equipment, creating an installed base in clinics. The device generates upfront revenue upon sale or placement, with potential for service and support contracts.

otonexus.com
2Single-Use Disposable Tips (Razor/Razorblade)
TypeHardware Sales
Description

Each exam uses a single-use disposable tip which supports infection control and generates repeat purchase volume tied directly to utilization. As adoption grows and exam volume increases, consumable demand scales with the installed base, creating recurring revenue alongside device sales.

otonexus.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Novoscope
Description

The ultrasound otoscope product developed by OtoNexus for instant, accurate assessment of middle ear infections using miniaturized ultrasound sensor embedded in ear speculum tip

otonexus.com
Core offering1 text field

OtoNexus is developing the Novoscope, a handheld ultrasound otoscope that miniaturizes through-air ultrasound sensors into the ear speculum tip to detect middle ear fluid and differentiate bacterial from viral infections in approximately 2 seconds at the point of care. The product combines a capital device (the Novoscope) with single-use disposable speculum tips in a razor/razorblade model, generating recurring consumables revenue alongside device sales. The device integrates with electronic medical records (EMR) and is targeted at pediatricians, primary care physicians, nurse practitioners, and physician assistants diagnosing middle ear infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results delivered in 2 seconds compared to traditional otoscopy subjective assessment
+2 more records
Product overview1 text field

OtoNexus Medical Technologies Inc. is developing the Novoscope ultrasound otoscope as its core medical device product—a handheld, ultrasound-based diagnostic tool that fits in a lab coat pocket and delivers instant, objective middle-ear assessment at the point of care. The company employs a razor/razorblade commercial model, combining capital device placement (the Novoscope) with recurring consumables revenue from single-use disposable tips. The Novoscope is designed for use by physicians, nurse practitioners, and physician assistants in frontline settings, with results delivered in seconds through a simplified one-button workflow. The device integrates directly with electronic medical records for seamless data transfer.

Product and service2 records
1Novoscope Ultrasound Otoscope
CategoryDiagnostic Medical Devices
Description

A handheld point-of-care ultrasound otoscope that miniaturizes a through-air ultrasound sensor within the ear speculum tip to detect middle ear effusion and characterize infection type, supporting differentiation of bacterial from viral infections in approximately 2 seconds. Designed for physicians, nurse practitioners, and physician assistants in frontline pediatric and primary care settings, with one-button workflow and direct EMR integration. Sold or placed as capital equipment to healthcare clinics under a razor/razorblade model.

2Single-Use Disposable Speculum Tips
CategoryMedical Device Consumables
Description

Disposable ear speculum tips designed for one-time per-patient use with the Novoscope ultrasound otoscope. These single-use tips ensure infection control compliance and generate recurring consumables revenue tied directly to device utilization as part of OtoNexus's razor/razorblade commercial model. The tips are universal-sized to fit patients from newborn to 18 years of age.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-11-12
Description

OtoNexus partnered with Fraunhofer IPMS to continue the development of ultrasound transducers. Fraunhofer IPMS is a renowned German research organization specializing in microelectronics and microsystems technology.

2Consortium for Technology & Innovation in Pediatrics (CTIP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Accepted into prestigious pediatric medical device accelerator based at Lurie Children's Hospital and Children's Hospital Los Angeles. CTIP is funded by FDA Pediatric Device Consortia grant program and provides access to clinical, engineering, regulatory, and commercial experts across 25 organizations in 8 states.

otonexus.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Selected from over 1,100 applications to participate in flagship four-month Showcase and Accelerator program, culminating at MedTech Conference powered by AdvaMed.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Selected for Faculty Seed Grant 2021-2022 program sponsored by Baylor College of Medicine Office of Research to pilot clinical studies with novel pediatric medical devices.

5Philadelphia Pediatric Medical Device Consortium
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pediatric device consortium providing support and resources for device development.

otonexus.com
6Advanced Medical Technology Association (AdvaMed)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Received AdvaMed scholarship for Innovation Showcase at MedTech Conference, the leading event for medical technology professionals in North America.

otonexus.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Selected as FiReStarter Company (2016), Company of the Year (2019), and Innovation Partner (2022). FiRe is described by The Economist as 'The best technology conference in the world' and has been highly accurate in predicting tech trends.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CTIP accelerator is based at these two premier children's hospitals, providing access to clinical expertise and hospital networks for pediatric device development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TytoCare develops a handheld telehealth device that includes an otoscope attachment for remote ear examination. Direct peer because both companies target point-of-care ear diagnostics with dedicated hardware consumables sold to primary care and pediatric providers.

TypeBroad incumbent
Description

Welch Allyn is the historic market leader in traditional pneumatic and digital otoscopes used by primary care worldwide. As the incumbent in the otoscope category, it represents the device OtoNexus must displace in clinical workflows.

TypeDirect peer
Description

CellScope developed a smartphone-attached otoscope for parent and clinician ear examinations, positioning itself as a digital diagnostic alternative. Direct peer as both companies target ear infection diagnosis with technology-augmented alternatives to traditional otoscopy.

TypeBroad incumbent
Description

Butterfly Network produces handheld, AI-enabled ultrasound devices for point-of-care use across multiple clinical applications. Broad incumbent as it shares the handheld ultrasound technology paradigm and broad point-of-care diagnostic positioning, though not ear-specific.

TypeEmerging player
Description

Clarius develops handheld wireless ultrasound scanners for various clinical applications. Emerging peer because it shares the miniaturized-ultrasound-for-point-of-care thesis, though its current applications are not focused on ear diagnostics.

TypeEmerging player
Description

Sonivate developed finger-mounted ultrasound probes for point-of-care imaging. Emerging peer because both companies pioneer novel form-factor ultrasound technology that could compete in adjacent point-of-care diagnostic niches.

TypeDirect peer
Description

Preceptis Medical developed the Hummingbird device for in-office pediatric ear tube placement, addressing pediatric ENT procedures. Direct peer because it targets the same pediatric otology/ENT clinical specialty and channels through children's hospitals.

TypeBroad incumbent
Description

Olympus is a global leader in ENT endoscopy and surgical devices used in otolaryngology. Broad incumbent because it serves the same ENT clinical call point with a broad portfolio and possesses the scale to acquire or partner with innovative point-of-care players like OtoNexus.

TypeBroad incumbent
Description

Smith+Nephew acquired Tusker Medical, which developed in-office pediatric ear tube solutions for otitis media. Broad incumbent because it now competes in the same pediatric otitis media treatment pathway, providing a potential strategic acquirer or partner.

TypeEmerging player
Description

Eko Health makes AI-enabled digital stethoscopes and point-of-care diagnostic tools for primary care. Emerging peer as both companies target frontline clinicians with AI-powered diagnostic hardware addressing high-prevalence conditions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OtoNexus Medical Technologies Inc.

Diagnostic Medical Devicesotonexus.com

OtoNexus Medical Technologies is a pre-revenue medical device company developing the Novoscope, an AI-driven ultrasound otoscope that detects bacterial middle ear infections in pediatric and primary care settings through a razor/razorblade model combining a capital device with single-use disposable tips.

What OtoNexus Medical Technologies Inc. does

OtoNexus Medical Technologies Inc. is a pre-revenue, venture-backed medical device company developing the Novoscope, a handheld ultrasound otoscope that miniaturizes a through-air ultrasound sensor into the tip of a disposable ear speculum and applies a proprietary algorithm to detect middle ear effusion and differentiate bacterial from viral infections in approximately two seconds. The technology is housed in a point-of-care device intended to replace subjective conventional otoscopy for frontline pediatric and primary-care decision-making, with direct EMR integration to transfer exam results, images, and video into patient records. The company was founded by Dr. George Gates, a practicing ENT surgeon, and Dr. Mark Moehring, an ultrasound systems expert and inventor of 16 issued ultrasound patents, and is led by Chair and CEO Caitlin Cameron with a leadership team drawn from Philips Healthcare, Fujifilm SonoSite, GE Healthcare, and Verathon.

The company protects its platform with more than 110 granted patents covering the through-air ultrasound modality, transducer design, and proprietary classification algorithm, and was selected for the FDA Safer Technologies Program (STeP) in December 2023, providing structured FDA engagement and an expedited review pathway. The commercial model is razor/razorblade: the Novoscope is sold or placed as durable capital equipment in clinics, while each exam consumes a single-use disposable tip, creating recurring consumables revenue that scales with installed base utilization. Target customers are primary care physicians, pediatricians, nurse practitioners, and physician assistants, with secondary segments in children's hospitals, pediatric emergency departments, and payers seeking to reduce unnecessary antibiotic prescriptions and downstream costs from misdiagnosed otitis media.

OtoNexus is headquartered near Seattle, Washington, is classified as a Micro Company (11-50 employees), and has raised approximately $13 million in equity from Keiretsu Capital and Keiretsu Forum members since inception, supplemented by non-dilutive SBIR grants from NIH ($1.15 million Fast-Track in 2017) and NSF (Phase I, Phase II, and Phase IIB). The company has built clinical and development partnerships with Fraunhofer IPMS for transducer co-development, with Mayo Clinic and Mary Bridge Children's Hospital for clinical validation, and is a member of three pediatric device consortia (CTIP, Southwest Pediatric Device Consortium, Philadelphia Pediatric Medical Device Consortium). Products are not yet commercially available, and the company is positioning itself for market entry pending FDA clearance.

OtoNexus Medical Technologies Inc. firmographics

Firmographics
Name
OtoNexus Medical Technologies Inc.
Legal name
OtoNexus Medical Technologies Inc.
Website
https://otonexus.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
OtoNexus Medical Technologies is a pre-revenue medical device company developing the Novoscope, an AI-driven ultrasound otoscope that detects bacterial middle ear infections in pediatric and primary care settings through a razor/razorblade model combining a capital device with single-use disposable tips.
Ownership category
akta.pro rank

OtoNexus Medical Technologies Inc. industry classification

Industry
Product category
Diagnostic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)

Keywords

  • Medical device diagnostics
  • Ultrasound otoscope technology
  • Ear infection detection
  • Pediatric medical devices
  • Antibiotic stewardship solutions

Where OtoNexus Medical Technologies Inc. is headquartered

Location

Headquarters

HQ city
Bellevue
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OtoNexus Medical Technologies Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Ultrasound Otoscope Device Sales: The ultrasound otoscope is sold (or placed) as durable capital equipment, creating an installed base in clinics. The device generates upfront revenue upon sale or placement, with potential for service and support contracts.
  2. Single-Use Disposable Tips (Razor/Razorblade): Each exam uses a single-use disposable tip which supports infection control and generates repeat purchase volume tied directly to utilization. As adoption grows and exam volume increases, consumable demand scales with the installed base, creating recurring revenue alongside device sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

OtoNexus Medical Technologies Inc. product offering

Product offering

Core offering

OtoNexus is developing the Novoscope, a handheld ultrasound otoscope that miniaturizes through-air ultrasound sensors into the ear speculum tip to detect middle ear fluid and differentiate bacterial from viral infections in approximately 2 seconds at the point of care. The product combines a capital device (the Novoscope) with single-use disposable speculum tips in a razor/razorblade model, generating recurring consumables revenue alongside device sales. The device integrates with electronic medical records (EMR) and is targeted at pediatricians, primary care physicians, nurse practitioners, and physician assistants diagnosing middle ear infections.

Product overview

OtoNexus Medical Technologies Inc. is developing the Novoscope ultrasound otoscope as its core medical device product—a handheld, ultrasound-based diagnostic tool that fits in a lab coat pocket and delivers instant, objective middle-ear assessment at the point of care. The company employs a razor/razorblade commercial model, combining capital device placement (the Novoscope) with recurring consumables revenue from single-use disposable tips. The Novoscope is designed for use by physicians, nurse practitioners, and physician assistants in frontline settings, with results delivered in seconds through a simplified one-button workflow. The device integrates directly with electronic medical records for seamless data transfer.

Differentiator

Problem solved

Functional benefit

Brands

  • Novoscope: The ultrasound otoscope product developed by OtoNexus for instant, accurate assessment of middle ear infections using miniaturized ultrasound sensor embedded in ear speculum tip

Products and services

  • Novoscope Ultrasound Otoscope A handheld point-of-care ultrasound otoscope that miniaturizes a through-air ultrasound sensor within the ear speculum tip to detect middle ear effusion and characterize infection type, supporting differentiation of bacterial from viral infections in approximately 2 seconds. Designed for physicians, nurse practitioners, and physician assistants in frontline pediatric and primary care settings, with one-button workflow and direct EMR integration. Sold or placed as capital equipment to healthcare clinics under a razor/razorblade model.
  • Single-Use Disposable Speculum Tips Disposable ear speculum tips designed for one-time per-patient use with the Novoscope ultrasound otoscope. These single-use tips ensure infection control compliance and generate recurring consumables revenue tied directly to device utilization as part of OtoNexus's razor/razorblade commercial model. The tips are universal-sized to fit patients from newborn to 18 years of age.

Quantifiable outcome

  • Results delivered in 2 seconds compared to traditional otoscopy subjective assessment
  • +2 more outcomes

Companies that use OtoNexus Medical Technologies Inc.

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

OtoNexus Medical Technologies Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature6 records

OtoNexus Medical Technologies Inc. partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Fraunhofer IPMS (Dresden, Germany)coreTechnology or Integration · 12 November 2018OtoNexus partnered with Fraunhofer IPMS to continue the development of ultrasound transducers. Fraunhofer IPMS is a renowned German research organization specializing in microelectronics and microsystems technology.
  • Consortium for Technology & Innovation in Pediatrics (CTIP)coreStrategic or Co-development PartnerAccepted into prestigious pediatric medical device accelerator based at Lurie Children's Hospital and Children's Hospital Los Angeles. CTIP is funded by FDA Pediatric Device Consortia grant program and provides access to clinical, engineering, regulatory, and commercial experts across 25 organizations in 8 states.
  • MedTech InnovatorcoreStrategic or Co-development PartnerSelected from over 1,100 applications to participate in flagship four-month Showcase and Accelerator program, culminating at MedTech Conference powered by AdvaMed.
  • Southwest Pediatric Device ConsortiumminorStrategic or Co-development PartnerSelected for Faculty Seed Grant 2021-2022 program sponsored by Baylor College of Medicine Office of Research to pilot clinical studies with novel pediatric medical devices.
  • Philadelphia Pediatric Medical Device ConsortiumminorStrategic or Co-development PartnerPediatric device consortium providing support and resources for device development.
  • Advanced Medical Technology Association (AdvaMed)minorStrategic or Co-development PartnerReceived AdvaMed scholarship for Innovation Showcase at MedTech Conference, the leading event for medical technology professionals in North America.
  • Future in Review (FiRe)coreStrategic or Co-development PartnerSelected as FiReStarter Company (2016), Company of the Year (2019), and Innovation Partner (2022). FiRe is described by The Economist as 'The best technology conference in the world' and has been highly accurate in predicting tech trends.
  • Lurie Children's Hospital and Children's Hospital Los AngelescoreStrategic or Co-development PartnerCTIP accelerator is based at these two premier children's hospitals, providing access to clinical expertise and hospital networks for pediatric device development.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

OtoNexus Medical Technologies Inc. competitors and assessment

Company assessment

Direct peers

  • TytoCare: TytoCare develops a handheld telehealth device that includes an otoscope attachment for remote ear examination. Direct peer because both companies target point-of-care ear diagnostics with dedicated hardware consumables sold to primary care and pediatric providers.
  • CellScope (Jawku Health): CellScope developed a smartphone-attached otoscope for parent and clinician ear examinations, positioning itself as a digital diagnostic alternative. Direct peer as both companies target ear infection diagnosis with technology-augmented alternatives to traditional otoscopy.
  • Preceptis Medical: Preceptis Medical developed the Hummingbird device for in-office pediatric ear tube placement, addressing pediatric ENT procedures. Direct peer because it targets the same pediatric otology/ENT clinical specialty and channels through children's hospitals.

Broad incumbents

  • Welch Allyn (Hillrom, now part of Baxter): Welch Allyn is the historic market leader in traditional pneumatic and digital otoscopes used by primary care worldwide. As the incumbent in the otoscope category, it represents the device OtoNexus must displace in clinical workflows.
  • Butterfly Network: Butterfly Network produces handheld, AI-enabled ultrasound devices for point-of-care use across multiple clinical applications. Broad incumbent as it shares the handheld ultrasound technology paradigm and broad point-of-care diagnostic positioning, though not ear-specific.
  • Olympus Medical: Olympus is a global leader in ENT endoscopy and surgical devices used in otolaryngology. Broad incumbent because it serves the same ENT clinical call point with a broad portfolio and possesses the scale to acquire or partner with innovative point-of-care players like OtoNexus.
  • Smith+Nephew (Tusker Medical): Smith+Nephew acquired Tusker Medical, which developed in-office pediatric ear tube solutions for otitis media. Broad incumbent because it now competes in the same pediatric otitis media treatment pathway, providing a potential strategic acquirer or partner.

Emerging players

  • Clarius Mobile Health: Clarius develops handheld wireless ultrasound scanners for various clinical applications. Emerging peer because it shares the miniaturized-ultrasound-for-point-of-care thesis, though its current applications are not focused on ear diagnostics.
  • Sonivate Medical: Sonivate developed finger-mounted ultrasound probes for point-of-care imaging. Emerging peer because both companies pioneer novel form-factor ultrasound technology that could compete in adjacent point-of-care diagnostic niches.
  • Eko Health: Eko Health makes AI-enabled digital stethoscopes and point-of-care diagnostic tools for primary care. Emerging peer as both companies target frontline clinicians with AI-powered diagnostic hardware addressing high-prevalence conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

OtoNexus Medical Technologies Inc. social profiles

Digital presence

OtoNexus Medical Technologies Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OtoNexus Medical Technologies Inc. leadership team

Management profile

Number of profiles

Profiles13 records

OtoNexus Medical Technologies Inc. funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OtoNexus Medical Technologies Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OtoNexus Medical Technologies Inc.

What does OtoNexus Medical Technologies Inc. do?

OtoNexus is developing the Novoscope, a handheld ultrasound otoscope that miniaturizes through-air ultrasound sensors into the ear speculum tip to detect middle ear fluid and differentiate bacterial from viral infections in approximately 2 seconds at the point of care. The product combines a capital device (the Novoscope) with single-use disposable speculum tips in a razor/razorblade model, generating recurring consumables revenue alongside device sales. The device integrates with electronic medical records (EMR) and is targeted at pediatricians, primary care physicians, nurse practitioners, and physician assistants diagnosing middle ear infections.

Is OtoNexus Medical Technologies Inc. a public or private company?

OtoNexus Medical Technologies Inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was OtoNexus Medical Technologies Inc. founded?

OtoNexus Medical Technologies Inc. was founded in 2016. It employs 11 to 50 people.

Where is OtoNexus Medical Technologies Inc. based?

OtoNexus Medical Technologies Inc. is headquartered in Bellevue, United States, in the North America region.

How does OtoNexus Medical Technologies Inc. make money?

Two revenue lines are on record. Ultrasound Otoscope Device Sales are the primary driver. The others are single-Use Disposable Tips (Razor/Razorblade).

Who are OtoNexus Medical Technologies Inc.'s main competitors?

Direct peers on record are TytoCare, CellScope (Jawku Health) and Preceptis Medical. Broad incumbents are Welch Allyn (Hillrom, now part of Baxter), Butterfly Network, Olympus Medical and Smith+Nephew (Tusker Medical). Emerging players are Clarius Mobile Health, Sonivate Medical and Eko Health.

Does OtoNexus Medical Technologies Inc. have an API?

No public API is recorded for OtoNexus Medical Technologies Inc..

What industry is OtoNexus Medical Technologies Inc. in?

OtoNexus Medical Technologies Inc.'s product category is Diagnostic Medical Devices. Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Janeasystems4 Power Management Strategies for Edge AI DevicesThe article outlines four primary strategies for managing power in edge AI devices, focusing on hardware-software co-design, ML model optimization, dynamic system management, and platform selection. It highlights specific techniques such as pruning, quantization, and duty cycling to extend battery life and reduce heat in resource-constrained environments like healthcare IoT. The text also references Janea Systems' engineering work on the OtoNexus Novoscope device and PyTorch porting to ARM64 as examples of these principles in practice.PR NewswireOtoNexus Medical Technologies Ranks #4 Among Micro Companies on Puget Sound Business Journal's 2025 Washington's Best WorkplacesOtoNexus Medical Technologies was named to Puget Sound Business Journal's Washington's Best Workplaces for 2025, ranking #4 in the Micro Companies category. The recognition was based on employee surveys evaluating workplace engagement, leadership, benefits, and practices.YahooOtoNexus Medical Technologies Accepted into Prestigious Pediatric Medical Device Accelerator, CTIPOtoNexus Medical Technologies was accepted into the CTIP pediatric medical device accelerator, a program funded by the FDA. The company's ultrasound-based device diagnoses middle ear infections, aiming to reduce unnecessary antibiotic use. The accelerator includes 25 organizations across eight states.PR NewswireOtoNexus Medical Technologies Accepted into Prestigious Pediatric Medical Device Accelerator, CTIPOtoNexus Medical Technologies was accepted into the Consortium for Technology & Innovation in Pediatrics (CTIP) accelerator. The program, funded by the FDA Pediatric Device Consortia, aims to advance pediatric medical devices, and OtoNexus will gain access to experts and a network of 25 organizations.BioSpaceOtoNexus Medical Technologies Selected for Elite FDA STeP ProgramOtoNexus Medical Technologies has been selected for the FDA's Safer Technologies Program (STeP), which provides expedited review and development support for innovative medical devices. This selection allows the company to collaborate closely with the FDA to accelerate market clearance for its Novoscope ultrasound otoscope, a device designed to differentiate bacterial middle ear infections.PR NewswireOtoNexus Medical Technologies Honored as a Top 100 Best Place to Work in Washington StateOtoNexus Medical Technologies has been recognized as one of Washington's 100 Best Workplaces by Puget Sound Business Journal, ranking among 25 small businesses selected for the honor. The award results from a rigorous evaluation process including employee feedback and workplace practices, reflecting the company's commitment to fostering a collaborative and supportive environment. OtoNexus has developed the world's first hand-held medical device using miniaturized ultrasound technology for instant assessment of middle ear infections.PR NewswireOtoNexus Medical Technologies Receives Prestigious National Science Foundation GrantOtoNexus Medical Technologies has been awarded the National Science Foundation SBIR Phase IIB Grant for its ultrasound platform technology designed to diagnose middle ear infections. The grant, based on results from prior phases and the technology's scientific merit and commercial potential, places the company among an elite group selected for extended funding. The platform aims to enable more precise diagnosis to help combat antibiotic resistance by reducing unnecessary antibiotic prescriptions.Wamda.comMindshift Capital invests in US medtech startupMindshift Capital invested in OtoNexus Medical Technologies' Series C raise, its eighth investment in the fund. OtoNexus developed a handheld ultrasound device to evaluate middle ear infections, improving diagnostic accuracy from about 50% to results within 2 seconds. The company targets a 50% reduction in antibiotic use for these infections.PR NewswireOtoNexus Medical Technologies Wins 2020 Red Herring Top 100 North America AwardOtoNexus Medical Technologies was named a winner of the Red Herring Top 100 North America 2020 award, selected from thousands of entrants and announced at a virtual conference on November 17-18, 2020. The company has developed the world's first ultrasound hand-held device for evaluating middle ear infections in children, with the goal of improving diagnostic accuracy and reducing unnecessary antibiotic prescriptions. CEO Caitlin Cameron stated the recognition validates the company's dual mission of improving pediatric care while offering a strong investment opportunity.PR NewswireOtoNexus Medical Technologies Wins Prestigious Most Valued Company Award at Keiretsu Forum Investor Capital ExpoOtoNexus Medical Technologies was named 'Most Valued Company' at the virtual Keiretsu Forum Investor Capital Expo, marking their third award from the world's largest angel investor network, which has over 3,000 members across 50 chapters on three continents. The company has developed the world's first handheld ultrasound device that can diagnose middle ear infections in under two seconds, addressing a condition that affects 93% of children and is the leading cause of antibiotic prescriptions and surgery in children. The award recognizes OtoNexus as a high-quality growth-stage opportunity in life sciences, with the device aiming to reduce unnecessary antibiotic usage by 50% and improve patient outcomes while lowering care costs.